SCHEMBL19933384

SCHEMBL19933384

Bc1nc(C(=O)NCC(=O)O)c(O)c(B)c1-c1cccc(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 18/20 0.57
EGLN3 Q9H6Z9 4/20 0.57
VEGFA P15692 3/20 0.57
FLT1 P17948 3/20 0.57
BBOX1 O75936 2/20 0.57
TET3 O43151 1/20 0.57
ASPH Q12797 1/20 0.57
TET2 Q6N021 1/20 0.57
KDM8 Q8N371 1/20 0.57
OGFOD1 Q8N543 1/20 0.57
TET1 Q8NFU7 1/20 0.57
HIF1AN Q9NWT6 1/20 0.57
FTO Q9C0B1 2/20 0.50
KDM5B Q9UGL1 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19933385 0.86 EGLN1 (0.58) EGLN1EGLN3VEGFAFLT1BBOX1
SCHEMBL19933404 0.84 EGLN1 (0.60) EGLN1EGLN3FLT1BBOX1FTO
SCHEMBL19933373 0.81 CNR2 (0.40) EGLN1EGLN3VEGFAFLT1BBOX1
SCHEMBL19933454 0.81 EGLN1 (0.65) EGLN1EGLN3VEGFAFLT1BBOX1
SCHEMBL19933512 0.81 EGLN1 (0.65) EGLN1EGLN3VEGFAFLT1BBOX1
SCHEMBL19933445 0.80 EGLN1 (0.59) EGLN1EGLN3VEGFAFLT1BBOX1
SCHEMBL19933380 0.78 EGLN1 (0.49) EGLN1BBOX1ASPHKDM8FTO
SCHEMBL19933409 0.76 EGLN1 (0.48) EGLN1EGLN3BBOX1FTOKDM5B
SCHEMBL28789305 0.74 EGLN1 (0.65) EGLN1EGLN3VEGFAFLT1BBOX1
SCHEMBL29721778 0.74 EGLN1 (0.65) EGLN1EGLN3VEGFAFLT1BBOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180065933-A1 DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS AKEBIA THERAPEUTICS, INC. (US) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065933-A1 DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS HIF1AN, EGLN3, EGLN2 EGLN1 6/4885EGLN3 2/4885VEGFA 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.